| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4029714 | Ophthalmology | 2007 | 9 Pages |
Abstract
The 6-month outcomes suggest intravitreal bevacizumab to be a promising treatment method for CNV secondary to PM, resulting in both visual and anatomic improvements. Treatment resulted in complete absence of angiographic leakage in 90.9% of eyes at 3 months. Further studies to evaluate the safety, efficacy, and optimal treatment regimen are justified.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Wai-Man FRCP, FRCOphth, Timothy Y.Y. MMedSc, FRCS, David T.L. MRCS, Dennis S.C. MD, FRCOphth,